Sarah Blair

Dr. Sarah Blair

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
SBSarah Blair
Sarah Blair
KTKari Thompson
Kari Thompson
JRJoseph Rococco
Joseph Rococco
VMVanessa Malcarne
Vanessa Malcarne
PBPeter D. Beitsch
Peter D. Beitsch
DODavid W. Ollila
David W. Ollila
The purpose of this survey was to ascertain the most common surgical practices for attaining negative (tumor-free) surgical margins in patients desiring breast-conservation treatment for breast cancer to see if a consensus exists for optimal treatment of patients. We sent a survey to 1,000 surgeons interested in the treatment of breast cancer. Three hundred eighty-one surgeons responded to this survey and 351 were used for the analysis (response rate of 38%). Answers showed a large variety in clinical practices among breast surgeons across the country. There was little intraoperative margin analysis; only 48% of surgeons examine the margins grossly with a pathologist and even fewer used frozen sections or imprint cytology. Decisions to reexcise specific margins varied greatly. For example, 57% of surgeons would never reexcise for a positive deep margin, but 53% would always reexcise for a positive anterior margin. Most importantly, there was a large range in answers about acceptable margins with ductal carcinoma in situ and invasive carcinoma. Fifteen percent of surgeons would accept any negative margin, 28% would accept a 1-mm negative margin, 50% would accept a 2-mm negative margin, 12% would accept a 5-mm negative margin, and 3% would accept a 10-mm negative margin. Results of this survey highlight the wide variety of practice patterns in the US for handling surgical margins in breast-conservation treatment. This issue remains controversial, with no prevailing standard of care. Consequently, additional study is needed in the modern era of multimodality treatment to examine the minimal amount of surgical treatment necessary, in conjunction with chemotherapy and radiation, to attain adequate local control rates in breast-conservation treatment.

20 August 2008 in Cancer
Verified
Journal Article
Open access
PDF file
JGJulia Grabowski
Julia Grabowski
SSSidney L. Salzstein
Sidney L. Salzstein
GSGeorgia Robins Sadler
Georgia Robins Sadler
SBSarah Blair
Sarah Blair
BACKGROUND.: Intracystic papillary carcinoma (IPC) is an uncommon breast neoplasm. To the authors' knowledge there are limited data regarding its epidemiology and only small studies focusing on outcomes. By using a large, population‐based database, this study aimed to identify specific characteristics of patients with IPC, investigate its natural history, and determine its long‐term prognosis.METHODS.: The California Cancer Registry (CCR), a population‐based registry, was reviewed from the years 1988 through 2005. The data were analyzed with regard to patient sex, age at presentation, tumor stage, and overall survival. Cumulative relative actuarial survival was determined using a Berkson‐Gage life table method. The CCR classifies IPC as either in situ (CIS) or invasive, as determined by the local pathologist.RESULTS.: A total of 917 cases of IPC were identified. Approximately 47% of cases (n = 427) were CIS, whereas 53% of cases had invasion (n = 490). The majority of the invasive cases were localized at the time of diagnosis (89.6%; n = 439). At 10 years, patients with CIS and invasive disease had a similar relative cumulative survival (96.8% and 94.4%; P = .18).CONCLUSIONS.: IPC is a rare disease. There is no apparently significant difference in the long‐term survival of patients in the 2 histologically derived subgroups of IPC. There is an excellent prognosis for patients diagnosed with IPC regardless of whether the tumor is diagnosed as in situ or invasive. Clinicians should keep this in mind when planning surgical and adjuvant treatments. Sentinel lymph node biopsy may be a prudent way to evaluate axillary involvement in patients with IPC. Cancer 2008. © 2008 American Cancer Society.

13 September 2010 in MedChemComm
Verified
Journal Article
Closed access
PDF file
HMH. Paul Martinez
H. Paul Martinez
YKYuko Kono
Yuko Kono
SBSarah Blair
Sarah Blair
SSSergio Sandoval
Sergio Sandoval
JWJessica Wang-Rodriguez
Jessica Wang-Rodriguez
WTWilliam C. Trogler
William C. Trogler
Hollow hard shell particles of 200 nm and 2 micron diameter with a 10 nm thick porous silica shell have been synthesized using polystyrene templates and a sol–gel process. The template ensures than the hollow particles are monodispersed, while the charged silica surface ensures that they remain suspended in solution for weeks. When filled with perfluorocarbon gas, the particles behave as an efficient contrast agent for colour Doppler ultrasound imaging in human breast tissue. The silica shell provides unique properties compared to conventional soft shell particles employed as ultrasound contrast agents: uniform size control, strong adsorption to tissue and cells immobilizing particles at the tissue injection site, a long imaging lifetime, and a silica surface that can be easily modified with biotargeting ligands or small molecules to adjust the surface charge and polarity.

24 July 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AWAnna Weiss
Anna Weiss
KLKatherine C. Lee
Katherine C. Lee
YRYajahira Romero
Yajahira Romero
EWErin Ward
Erin Ward
YKYeunjeong Kim
Yeunjeong Kim
SBSarah Blair
Sarah Blair

25 July 2011 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
KTKari Thompson
Kari Thompson
JGJulia Grabowski
Julia Grabowski
SSSidney L. Saltzstein
Sidney L. Saltzstein
GSGeorgia R. Sadler
Georgia R. Sadler
SBSarah Blair
Sarah Blair
Adenoid cystic carcinoma (ACC) is an uncommon type of breast cancer. There are limited data about its epidemiology, tumor characteristics, and outcomes. Using a large, population‐based data base, this study aimed to identify specific characteristics of patients with adenoid cystic breast cancer, investigate its natural history, and determine its long‐term prognosis. The California Cancer Registry, a population‐based registry, was reviewed from the years 1988 to 2006. The data were analyzed with relation to patient age, tumor size and stage, and overall survival. Relative cumulative actuarial survival was determined using the Berkson‐Gage life table method. A total of 244 cases of invasive adenoid cystic cancer were identified in women during this time period. The patients’ median age was 61.9 years. Most cases were diagnosed in non‐Hispanic White women (82%, n = 200), followed by African American (6%, n = 15), Asian/Pacific‐Islander (5.7%, n = 14) and Hispanic women (4.4%, n = 12). The remainder of the patients was of unknown or other ethnicity. Tumors were between 1 and 140 mm in size. At the time of diagnosis, 92% (n = 225) of patients had localized disease, 5% (n = 12) of patients had regional disease, and even fewer (n = 7) had either distant or unknown staged disease. Lymph node involvement was not present in any tumors smaller than 1.4 cm. The relative cumulative survival of patients with adenoid cystic breast carcinoma was 95.6% at 5 years and 94.9% at 10 years. ACC of the breast is a rare disease with an overall good prognosis. Knowing that this cancer usually presents as localized disease, with lymph node involvement seen only with larger tumors, can help clinicians plan the operative management of these tumors.

9 August 2006 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SBSarah Blair
Sarah Blair
MMMichele Mcelroy
Michele Mcelroy
MMMichael S. Middleton
Michael S. Middleton
CCChris Comstock
Chris Comstock
TWTanya Wolfson
Tanya Wolfson
JMJoanne Mortimer
Joanne Mortimer